Media stories about Proteon Therapeutics (NASDAQ:PRTO) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteon Therapeutics earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.1280878222267 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment’s analysis:

A number of brokerages recently issued reports on PRTO. Zacks Investment Research cut Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright set a $2.00 price objective on Proteon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. Finally, Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday, August 16th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.25.

Shares of Proteon Therapeutics (PRTO) traded up $0.10 on Tuesday, hitting $2.10. The stock had a trading volume of 68,681 shares, compared to its average volume of 110,942. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $11.45.

Proteon Therapeutics (NASDAQ:PRTO) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.11. sell-side analysts predict that Proteon Therapeutics will post -1.54 EPS for the current year.

WARNING: “Proteon Therapeutics (PRTO) Earns Daily Coverage Optimism Score of 0.00” was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/proteon-therapeutics-prto-earns-daily-coverage-optimism-score-of-0-00/1686160.html.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Insider Buying and Selling by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.